fees-transitional | Waivers, fees, transitional and application provisions, Schedule 5 and the endnotes: charges and fees, the 2010 to 2026 amendment transitions and the currency of this compilation | 0 |
r1.1-1.8 | Preliminary: name, dictionary, devices with a measuring function, refurbishment, common characteristics of a kind of device, nomenclature codes and health professionals who are not | 0 |
r10.1-10.7 | Miscellaneous machinery: authorised persons, implantable breast and cardiac device registries, delegations, software forms and reconsideration and tribunal review of decisions | 0 |
r10.2 | Sponsor identification: provide the sponsor's name and address with the device so users can readily identify the sponsor, located as clause 13.2 requires, and never let an added la | 0 |
r10.3-10.3A | Custom-made devices: notify the Secretary within 2 months of first manufacture in Australia or first import, and give an annual report on the approved form before 1 October coverin | 0 |
r2.1-3.1 | Essential principles and the classification scale: Schedule 1 sets the essential principles for section 41CA of the Act; devices are ranked I, IIa, IIb and III, and IVDs 1 to 4 | 0 |
r3.11-sch3-8 | Apply the clinical evaluation procedures to every device (custom-made devices included): obtain clinical investigation data or a documented literature review, evaluate it through c | 0 |
r3.12 | Provide all records and correspondence on the application of the conformity assessment procedures in English | 0 |
r3.2-3.3 | Classify every device by its intended purpose under Schedule 2 (non-IVD) or Schedule 2A (IVD), applying the regulation 3.3 principles for combinations, accessories, software, produ | 0 |
r3.4-3.10 | Apply the conformity assessment procedures the Regulations set for the device's class (or a higher class's procedures if preferred), including the extra steps for sterile, measurin | 0 |
r4.2-4.4 | Conformity assessment certificates: what the Secretary considers, decision time, priority applicant determinations, certificate content and suspension revocation timing | 0 |
r4.6-4.11 | Keep the certificate holder accurate: notify the Secretary within 3 months of the manufacturer's death, bankruptcy, winding up or change of name, apply within 3 months to change th | 0 |
r4A.1-4A.9 | Australian conformity assessment bodies: purpose, applications, assessment and duration of conformity assessment body determinations | 0 |
r4A.10-4A.16 | Australian conformity assessment bodies: comply with Schedule 3AA, tell the Secretary of substantial changes within 10 working days and of planned cessation, allow entry and inspec | 0 |
r4A.17-4A.18 | Australian conformity assessment bodies: certify only where an appropriate procedure has been applied, vary, suspend or revoke certificates when no longer satisfied, notify the Sec | 0 |
r5.10 | Automatic condition: record complaint and adverse event information and each distribution of the device as soon as practicable and keep the records 10 years for Class III, implanta | 0 |
r5.11 | Automatic condition: for Class III, implantable Class IIb and Class 4 IVD devices, give the Secretary an annual report before 1 October for the first three reporting periods after | 0 |
r5.12 | Automatic condition: for higher-risk IVDs, self-test and point-of-care IVDs and spinal fusion implants, notify the Secretary at least 20 business days before importing, supplying o | 0 |
r5.13 | Automatic condition: do not supply in Australia a device containing a scheduled poison where that supply would breach Part 2 of the current Poisons Standard | 0 |
r5.2-5.4D-6.1 | Inclusion in the Register: period to obtain manufacturer information, applications selected for mandatory audit, priority applicant determinations and suspension revocation timing | 0 |
r5.7 | Automatic condition: report adverse events to the Secretary within 48 hours for a serious public health threat, 10 days for a death or serious deterioration, 30 days where recurren | 0 |
r5.8-5.8A | Automatic condition: hold and give, when required, information on any malfunction, deterioration, design, labelling, instruction or advertising inadequacy or use that led to any co | 0 |
r5.9 | Automatic condition: store and transport devices under the sponsor's control in line with the manufacturer's instructions for use and accompanying information | 0 |
r7.2 | Category A patients: use an unapproved device only with informed consent and at the treating medical practitioner's direction, complete the approved Category A statement, and send | 0 |
r7.3-sch4-2.3 | Clinical trials: notify the Secretary (CTN) before the device is used and before each new site starts, approve the trial on ethics committee advice no less restrictively, give Nati | 0 |
r7.6-7.8 | Authorised prescribers: supply under an authority only as its directions allow, and when a health practitioner supplies a device under the authorised prescriber scheme notify the p | 0 |
r8.1A-8.1 | Answer information notices under section 41JA within the set period and keep manufacturing records for 5 years and distribution records for 10 years (Class III and implantable Clas | 0 |
r8AA | Healthcare facilities (hospitals and day hospitals): report to the TGA electronically adverse events involving Class III and Class 4 IVD devices within 10 days of a death or seriou | 0 |
r9A.1 | Australian Unique Device Identification Database: the Secretary establishes and maintains the database, limits personal information, retains entries during suspension or cancellati | 0 |
sch1-1 | Essential principle 1: design and produce the device so that, used as intended by suitably trained users, it does not compromise the patient's condition or anyone's safety, and its | 0 |
sch1-10 | Essential principle 10: a device with a measuring function must measure accurately, precisely and stably within stated limits, use ergonomic scales and express results in Australia | 0 |
sch1-11 | Essential principle 11: minimise patient, user and bystander exposure to intended and stray radiation, give users control and warnings for hazardous emissions, document radiation i | 0 |
sch1-12.1-a | Essential principle 12.1(1) to (4): programmed devices and software as a medical device must be safe, reliable, accurate, usable, secure and repeatable for their purpose, fail safe | 0 |
sch1-12.1-b | Essential principle 12.1(5) and (6): build and maintain cybersecurity by best practice (protection against unauthorised access, vulnerability management, patching, disclosure and u | 0 |
sch1-12.12-12.13 | Essential principles 12.12 and 12.13: devices that deliver energy or substances must set and hold the delivered rate and amount accurately, prevent accidental dangerous release, fl | 0 |
sch1-12.2-12.4 | Essential principles 12.2 to 12.4: where patient safety depends on power, provide a means to check an internal supply and an alarm for external power failure, and fit clinical-para | 0 |
sch1-12.5-12.11 | Essential principles 12.5 to 12.11: minimise electromagnetic interference with nearby equipment and protect people against electric shock, mechanical, vibration, noise, connector a | 0 |
sch1-13.1-13.3 | Essential principles 13.1 to 13.3: provide in English, legibly and in the right place (device, packaging or leaflet), the information that identifies the device and manufacturer an | 0 |
sch1-13.4 | Essential principle 13.4: supply instructions for use carrying every applicable clause 13.4 table item, unless a Class I, IIa or Class 1 IVD device can be used safely without them | 0 |
sch1-13.5-13.6 | UDI on the device: from the device's general start day provide the UDI device identifier and production identifier in human- and machine-readable form on the device, else its packa | 0 |
sch1-13A | Essential principle 13A: for implantable and active implantable devices in scope, make a patient implant card (or electronic equivalent) and a patient information leaflet (or elect | 0 |
sch1-13B | Essential principle 13B: make the current software version number and build number accessible and identifiable to users, in English | 0 |
sch1-13C.1 | UDI identifiers: obtain the UDI device identifier and packaging identifiers from a single UDI issuing agency and allocate production identifiers under that agency's rules | 0 |
sch1-13C.2-13C.4 | AusUDID entries: include each model's device identifier, issuing agency, packaging identifiers and the clause 13C.3 data elements within 30 days of first supply on or after the gen | 0 |
sch1-13C.5 | UDI direct marking: from the direct marking start day, directly mark reusable devices that are reprocessed between patients with the device and production identifiers, in both form | 0 |
sch1-14 | Essential principle 14: hold clinical evidence suited to the device's use and class that demonstrates compliance with the applicable essential principles | 0 |
sch1-15 | Essential principle 15: IVD devices must have analytical and clinical performance that supports the intended use, address accuracy, precision, sensitivity, specificity, stability, | 0 |
sch1-2 | Essential principle 2: choose design and construction solutions that follow safety principles and the state of the art, in the order identify hazards, design them out, protect agai | 0 |
sch1-3 | Essential principle 3: the device must perform as the manufacturer intends and be designed, produced and packaged to suit a therapeutic purpose within the definition of a medical d | 0 |
sch1-4 | Essential principle 4: within its stated safe-use life, under normal stresses and with maintenance and calibration done as instructed, the device must keep the safety and performan | 0 |
sch1-5 | Essential principle 5: design, produce and pack the device so that transport and storage done in line with the manufacturer's instructions do not degrade its characteristics or per | 0 |
sch1-6 | Essential principle 6: the benefits of using the device for its intended performance must outweigh any undesirable effects | 0 |
sch1-7.1-7.3 | Essential principles 7.1 to 7.3: select materials for their chemical and physical properties and biocompatibility, minimise contaminants and residues, and make the device safe with | 0 |
sch1-7.4 | Essential principle 7.4: where a device incorporates a substance that would be a medicine if used alone and acts ancillary to the device, verify the substance's safety and quality | 0 |
sch1-7.5-7.7 | Essential principles 7.5 to 7.7: minimise risks from substances leaching out, from unintended ingress or egress of substances, and from released particles, with particular attentio | 0 |
sch1-8.1-8.2 | Essential principles 8.1 and 8.2: eliminate or minimise infection risk, make the device easy to handle without cross-contamination, and control non-viable animal, microbial or reco | 0 |
sch1-8.3-8.5 | Essential principles 8.3 to 8.5: supply sterile devices sterile by a validated method in controlled conditions with packaging that keeps them sterile, pack non-sterile devices to k | 0 |
sch1-9 | Essential principle 9: make the device safe in combination with other devices and equipment and remove or minimise physical, environmental, interference, maintenance, ageing, accur | 0 |
sch3-1.3-1.4 | Full quality assurance: implement a quality management system covering design, production, packaging, labelling and final inspection, have it assessed, document it fully and build | 0 |
sch3-1.5-1.6 | Full quality assurance: notify and have assessed any substantial change to the system or to the devices it covers, and for Class III, Class 4 IVD and Class 4 in-house IVD devices a | 0 |
sch3-1.7-1.9 | Full quality assurance: on request give the Secretary system documentation, design and manufacturing data and arrange tests; make a signed declaration of conformity with the clause | 0 |
sch3-2 | Type examination: arrange examination of a representative sample with complete design, manufacturing, standards, test, clinical and labelling documentation, supply samples on reque | 0 |
sch3-3 | Verification: have each device or a statistical batch sample examined and tested against the approved type or the technical documentation, keep production uniform, operate post-mar | 0 |
sch3-4 | Production quality assurance: implement and have assessed a quality management system for production and final inspection that ensures devices match the approved type or technical | 0 |
sch3-5 | Product quality assurance: implement and have assessed a product quality management system for final inspection and testing of each device or batch sample against the approved type | 0 |
sch3-6.3-6.4 | Declaration of conformity route: prepare and keep current technical documentation that would let the Secretary assess compliance, covering description, design drawings, sterilisati | 0 |
sch3-6.5 | Declaration of conformity route: establish and keep up to date a post-marketing system that reviews post-production experience, applies corrective action and promptly notifies the | 0 |
sch3-6.6-6.7 | Declaration of conformity route: make a signed clause 6.6 declaration stating device identifiers, class, nomenclature code, any additional procedures and certificate numbers, and k | 0 |
sch3-6A | Class 1 to 3 in-house IVDs: notify the Secretary of every in-house IVD manufactured, maintain NATA (or approved body) accreditation to ISO 15189 or ISO/IEC 17025 and meet the NPAAC | 0 |
sch3-6B | Class 4 in-house IVDs: implement a quality management system for design to final inspection, meet the blood and tissue GMP code and licence or NATA ISO 15189 accreditation with the | 0 |
sch3-7.2 | Custom-made devices: prepare and supply with each device a signed statement identifying the device, patient, requesting health professional and design characteristics and confirmin | 0 |
sch3-7.5 | System or procedure packs: make a signed clause 7.5 declaration confirming conformity evidence for each device, registered medicines, compatible contents used within intended purpo | 0 |
sch3A | Unused emergency medical devices: when an emergency exemption ends, notify the devices on hand, store and dispose of them as the Secretary directs (destruction, export, supply or r | 0 |
sch4-2.12-2.13 | Custom-made device exemption conditions: the manufacturer (or, for imports, the sponsor's procedures) must keep conformity or design and manufacturing information available, allow | 0 |
sch4-2.14-2.20 | Conditional exemptions for patient-matched devices, clinical decision support software, Class 1 to 4 in-house IVDs for specified purposes, surgical loan kits, therapeutic vaping de | 0 |